Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single‐Inhaler Long‐Acting Dual Bronchodilators
The Clinical Respiratory Journal · 2026
DOI: 10.1111/crj.70173 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Clinical Respiratory Journal, 2026. Verfasst von Yimeng Lu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Bronchodilator Agents, Quinuclidines, Quinolones. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System, The Construction of Multi-Disciplinary Treatment System for Severe Pneumonia, National Natural Science Foundation of China.
Themen: COPD
Abstract (Originalsprache)
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation. While single‐inhaler long‐acting dual bronchodilators (LADBs) effectively relieve symptoms and improve lung function, their long‐term impact on spirometry outcomes and the potential for meaningful changes in key diagnostic indices in a real‐world setting remain underexplored.
Methods
This was a single‐country (China), single‐center, retrospective, noninterventional, real‐world study that included 182 patients treated with LADBs (indacaterol/glycopyrronium [IND/GLY] or umeclidinium/vilanterol [UMEC/VI]). The primary outcomes were changes in trough FEV1 and FEV1/FVC from baseline. Secondary outcomes were changes in other spirometry parameters. An exploratory post hoc analysis explored the reversal of FEV1/FVC, defined as a posttreatment trough FEV1/FVC ratio that exceeded 70%.
Results
Single‐inhaler LADB therapy significantly improved lung function, including FEV1, FVC, FEV1/FVC, RV, and parameters of small airway function. The least‐square mean change in trough FEV1 and FEV1/FVC post‐treatment was 0.154 L [95% CI: 0.09, 0.218] and 1.929% [95% CI: 0.694, 3.164], respectively, at 24 weeks. Posttreatment FEV1 exhibited a characteristic pattern: an initial increase, followed by a peak, a subsequent slight decline, and eventual stabilization. Patients with lower GOLD grades experienced greater improvement in key spirometry parameters. Notably, 21 patients (11.5%) achieved a reversal of the FEV1/FVC ratio to over 70%. Exploratory logistic regression showed that a better baseline lung function, especially FEV1/FVC ratio, was associated with an increased likelihood of achieving this threshold (OR = 1.52 [95% CI: 1.29, 1.89]).
Conclusion
This study demonstrated significant and sustained improvements in lung function in this real‐world cohort of COPD patients managed with LABA/LAMA monotherapy. A subset of patients achieved a posttreatment FEV1/FVC ratio above 70%, indicating a potentially meaningful change in airflow limitation after LADB therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
- School of Information Science and Technology, Fudan University, Shanghai, China.
- Shanghai Key Laboratory of Lung Inflammation and Injury, Department of Pulmonary Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
- Shanghai Institute of Infectious Disease and Biosecurity, Shanghai, China.
- Shanghai Respiratory Research Institute, Shanghai, China.
- National and Shanghai Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Yimeng Lu, Yanan Zhou, Weipeng Jiang
Förderung
- Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System
- The Construction of Multi-Disciplinary Treatment System for Severe Pneumonia
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- R&D Program of Guangzhou National Laboratory
- Shanghai Municipal Science and Technology Major Project
- Shanghai Municipal Key Clinical Specialty
Zitieren
APA
Lu, Y., Zhou, Y., Xue, L., Tian, H., Han, J., Yang, Y., Guo, Y., Jiang, W., Chen, C., Wang, L., & Song, Y. (2026). Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single‐Inhaler Long‐Acting Dual Bronchodilators. The Clinical Respiratory Journal. https://doi.org/10.1111/crj.70173
Vancouver
Lu Y, Zhou Y, Xue L, Tian H, Han J, Yang Y, et al. Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single‐Inhaler Long‐Acting Dual Bronchodilators. The Clinical Respiratory Journal. 2026. doi:10.1111/crj.70173
BibTeX
@article{Lu2026,
author = {Lu, Yimeng and Zhou, Yanan and Xue, Liping and Tian, Hao and Han, Junjie and Yang, Yanping and Guo, Yunxin and Jiang, Weipeng and Chen, Cuicui and Wang, Linlin and Song, Yuanlin},
title = {Temporal and Partial Reversal of Airflow Limitation in Patients With COPD Treated With Single‐Inhaler Long‐Acting Dual Bronchodilators},
journal = {The Clinical Respiratory Journal},
year = {2026},
doi = {10.1111/crj.70173}
}
EUVIMED